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Abstract 
Background: Brain‑derived neurotrophic factor (BDNF) has neuroprotective, proangiogenic and myogenic effects 
and, therefore, possibly acts as a psychosomatic mediator. Here, we measured serum BDNF (seBDNF) level in hyper‑
tensive patients (HT) and healthy controls (CONT) and its relation to affective temperaments, depression and anxiety 
scales, and arterial stiffness parameters.
Methods: In this cross‑sectional study, affective temperaments, anxiety, and depression were studied with question‑
naires (TEMPS‑A, HAM‑A, and BDI, respectively). SeBDNF level and routine laboratory parameters were measured as 
well. Arterial stiffness was evaluated with a tonometric method.
Results: Allover, 151 HT, and 32 CONT subjects were involved in the study. SeBDNF level was significantly higher in 
HT compared to CONT (24880 ± 8279 vs 21202.6 ± 6045.5 pg/mL, p < 0.05). In the final model of regression analy‑
sis, hyperthymic temperament score (Beta = 405.8, p = 0.004) and the presence of hypertension (Beta = 6121.2, 
p = 0.001) were independent determinants of seBDNF. In interaction analysis, it was found that in HT, a unit increase 
in hyperthymic score was associated with a 533.3 (95 %CI 241.3–825.3) pg/mL higher seBDNF. This interaction was 
missing in CONT.
Conclusions: Our results suggest a complex psychosomatic involvement of BDNF in the pathophysiology of hyper‑
tension, where hyperthymic affective temperament may have a protective role. BDNF is not likely to have an effect on 
large arteries.
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Background
Brain-derived neurotrophic factor (BDNF) is a member 
of the neurotrophic factor family, playing a central role 
in the regulation of neuronal growth, maintenance, and 
survival [1]. Its involvement in psychiatric conditions is 
well described and was confirmed by a meta-analysis, 
as in major depressive disorder, the decreased serum 
BDNF (seBDNF) level was elevated following a course 
of antidepressant treatment [2]. In addition to its neu-
rotrophic effects, BDNF has proangiogenic features as 
well. The importance of BDNF was suggested also in high 
cardiovascular risk conditions, such as obesity, meta-
bolic syndrome, and coronary atherosclerosis [3–5]. It is 
hypothesized to play a protective role in cardiovascular 
pathophysiology as its higher serum level was found to be 
associated with decreased risk of cardiovascular disease 
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and mortality [6]. It was demonstrated that circulating 
BDNF is influenced by age and gender [7], the presence 
of diabetes [8], and the use of benzodiazepines in differ-
ent neurological diseases [9], correlates with total choles-
terol [4], and BDNF is stored and released from platelets 
during activation [10]. Hypertension has widely studied 
psychosomatic connections [11, 12]; however, the role of 
BDNF in this condition has not been extensively evalu-
ated yet.
Affective temperament types (depressive, cyclothymic, 
hyperthymic, irritable, and anxious) are subclinical, trait-
related manifestations and commonly the antecedents 
of minor and major mood disorders [13]. Previously, we 
clarified an association between dominant cyclothymic 
affective temperament and hypertension [14]. Recently, 
we demonstrated decreased seBDNF level in chronic 
hypertensive patients with dominant anxious, irritable, 
depressive or cyclothymic temperaments compared with 
hypertensive controls without dominant temperaments 
[15]. However, the association between affective tem-
perament scores, as continuous variables and seBDNF in 
chronic hypertension, has not been clarified yet.
Arterial stiffening is increasingly recognized as an inde-
pendent risk factor for cardiovascular diseases. Carotid–
femoral pulse wave velocity (PWV) is the most accepted 
non-invasive arterial stiffness parameter for cardiovascu-
lar risk assessment among hypertensive patients [16]. In 
different animal models, BDNF was shown to be vasore-
laxant not only on pulmonary arteries [17] but also on rat 
aortic rings [18]. Based on these data, a possible associa-
tion between the seBDNF level and different arterial stiff-
ness parameters can also be supposed in humans.
We hypothesized that as hypertension is a risk fac-
tor for cardiovascular diseases and BDNF is protective 
in cardiovascular pathology, seBDNF can be altered in 
hypertension. We also presumed that seBDNF is associ-
ated with different affective temperaments, depression, 
anxiety, and arterial stiffness parameters providing a new 
bridge of psychosomatic processes.
Methods
In this cross-sectional study, chronic (>12 months medi-
cation) well-controlled or grade 1 consecutive hyperten-
sive Caucasian patients (HT) and age-matched healthy 
controls (CONT) of three primary care practices were 
involved. All of the chronic hypertensive patients of our 
previous, pilot study [15] were involved into this study as 
well. Data of the involved subjects were analyzed for the 
relationship between the seBDNF level, routine labora-
tory parameters, affective temperaments, anxiety, depres-
sion, and arterial stiffness parameters. Exclusion criteria 
for HT were the presence of atrial fibrillation, treated 
depression, bipolar disorder or dementia posing an 
obstacle to completing questionnaires. Moderate use of 
the anxiolytic alprazolam (less than 0.5 mg/day) was not 
a restrictive criterion. In the case of CONT, the denial of 
consent was the only exclusion criterion.
Evaluation of affective temperaments, depression, 
and anxiety
The Temperament Evaluation of Memphis, Pisa, Paris 
and San Diego Autoquestionnaire (TEMPS-A) was used 
to assess affective temperaments on depressive, cyclo-
thymic, hyperthymic, irritable, and anxious subscales, 
requiring ‘yes’ (score 1) or ‘no’ (score 0) answers [19]. It 
contains 110 items (109 in the version for males), and the 
questions of the various temperament types are grouped 
together as follows:
1. depressive temperament: questions 1 to 21 (21 
points);
2. cyclothymic temperament: questions 22 to 42 (21 
points);
3. hyperthymic temperament: questions 23 to 63 (21 
points);
4. irritable temperament: questions 64 to 84 (21 points 
in women and 20 points in men version);
5. anxious temperament: questions 85 to 110 (26 
points).
The Beck depression inventory (BDI) is a 21-question 
multiple-choice self-report questionnaire, one of the 
widely used instruments for measuring the severity of 
depression. Participants are asked to make ratings on a 
four-point scale, where a higher score correlates with 
more severe depression [20].
Hamilton anxiety scale (HAM-A) was evaluated by the 
examiner to study the severity of anxiety. The scale con-
sists of 14 items, and each item is scored on a scale of 0 
(not present) to 4 (severe anxiety) [21].
Measures of blood pressure and arterial stiffness
Arterial stiffness parameters were evaluated with the 
validated tonometric PulsePen device (DiaTecne, Milan, 
Italy). Measurements were performed in a temperature-
controlled room in supine position, on the day of blood 
sampling, prior to it, between 7:00 and 8:00 a.m. Patients 
were asked to refrain from eating, smoking, and caffeine-
containing drinks in the morning of the procedure, but to 
take the regular blood pressure medication. Upon arrival 
after 5  min rest, two brachial blood pressure measure-
ments were taken on each arm in the sitting position with 
a validated oscillometric blood pressure device (Omron 
M3). The mean value of the higher side was further taken 
into calculation as brachial systolic (brachial SBP) and 
diastolic (brachial DBP) blood pressures and heart rate. 
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Next, subjects were equipped with arterial stiffness meas-
urement devices and then rested in the supine position for 
approximately 15  min before being measured. The mean 
of two successful measurements was used in the statistical 
calculations. In the PWV calculations, 80 % of the carotid–
femoral distance was used following the recent guide-
line [22]. Augmentation index (AI), central systolic blood 
pressure (cSBP), central pulse pressure (cPP), and pulse 
pressure amplification (PPAmp) were also calculated. As 
PulsePen calculates pressure values using brachial diastolic 
blood pressure calibration, the calculated central and bra-
chial diastolic blood pressure values were identical [23].
Measurement of seBDNF concentration
Peripheral blood samples of patients were collected in 
anticoagulant-free tubes, right after the measurement 
of arterial stiffness. After centrifugation (3600  rpm 
for 6  min), the serum was stored at −20  °C. SeBDNF 
was measured using commercially available sandwich 
enzyme-linked immunosorbent assay (R&D Systems, 
Minneapolis MN, USA) according to the manufacturer’s 
protocol, and serum BDNF level was determined in pg/
mL.
Statistical analysis
Normality of the parameters was tested with the Kol-
mogorov–Smirnov test. Descriptive characteristics, labo-
ratory, arterial stiffness parameters and TEMPS-A, BDI, 
HAM-A scores were compared between CONT and HT 
groups using unpaired Student’s t tests or Mann–Whitney 
rank sum test for data failing tests of normality. The equal-
ity of variances was studied with Levene’s test. Pearson 
correlation coefficients were calculated to study the rela-
tionship between seBDNF and all other factors measured. 
Hierarchic linear regression analysis was used to study 
the determinants of seBDNF in the whole population 
with a stepwise entry of variables with either previously 
described association with seBDNF or with a significant 
univariate correlation with seBDNF in the present data 
set. As a bidirectional association can be hypothesized 
between affective temperaments and hypertension [14], 
predetermined interaction analysis was performed to 
investigate moderation between hypertension and affec-
tive temperament scores on seBDNF level.
Data were expressed as mean ± standard deviation or 
mean with interquartile ranges. p < 0.05 was considered 
to be significant. SPSS 13.0 for Windows was used in 
calculations.
Results
Altogether, 151 HT and 32 CONT subjects were 
involved. Eleven of the invited HT and four CONT did 
not give their informed consent and were excluded. 
Baseline demographic and laboratory parameters, cur-
rent medication, TEMPS-A, BDI, and HAM-A scores, 
central blood pressure, and arterial stiffness parame-
ters as well as seBDNF levels are shown in Table 1. The 
median number of the used antihypertensive compounds 
was 2 (IQR: 2–3). Differences between CONT and HT 
were found in body weight and BMI, serum glucose, 
cholesterol, LDL and HDL, BDI and HAM-A scores, in 
the brachial and central systolic blood pressure and the 
brachial pulse pressure. SeBDNF was elevated in HT 
(Table 1). In the analysis of simple correlations, the fol-
lowing parameters were found to be associated signifi-
cantly with seBDNF: hypertension (r = 0.174, p = 0.018), 
serum cholesterol (r = 0.194, p = 0.009), LDL (r = 0.208, 
p = 0.015) and HDL level (r = 0.204, p = 0.006), platelet 
count (r  =  0.188, p  =  0.011), pulse pressure amplifica-
tion (r  =  0.157, p  =  0.037), and hyperthymic tempera-
ment score (r = 0.189, p = 0.010). Tendencies of inverse 
correlations were found with the presence of diabetes 
or the use of alprazolam, but these were not signifi-
cant (r  =  −0.114, p  =  0.12 and r  =  −0.103, p  =  0.16, 
respectively).
Table  2 demonstrates the results of hierarchical lin-
ear regression models. In the final model adjusted 
for all potential confounders, one unit increase in the 
hyperthymic score was associated with a 405.8  pg/mL 
higher seBDNF and the presence of hypertension with 
a 6121.2  pg/mL higher seBDNF. We found an interac-
tion (p = 0.002) between hypertension and hyperthymic 
temperament score on seBDNF in the whole study pop-
ulation: there was no significant association between 
hyperthymic score and seBDNF in CONT (p  =  0.545) 
and a unit increase in hyperthymic score was associated 
with a 533.3 (95 %CI 241.3–825.3) pg/mL higher seBDNF 
level in HT (p  <  0.001). The different impact of hyper-
thymic score in seBDNF in HT and CONT is shown in 
Fig. 1. 
Discussion
Here, we demonstrated for the first time in the literature 
that in chronic hypertensive patients, seBDNF is ele-
vated, and hyperthymic affective temperament score and 
the presence of hypertension are independent determi-
nants of seBDNF level. In hypertensive patients, the ele-
vation of hyperthymic temperament score is associated 
with the elevation of seBDNF; however, this association is 
not present in healthy subjects.
We suppose that the observed BDNF elevation in HT 
can be part of a protective compensatory mechanism tar-
geting peripheral neurons and vascular cells. BDNF has 
beneficial effects on the regulation of blood pressure, as 
it is involved not only in the development, but also in the 
survival of arterial baroreceptor system [24]. Vascular 
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endothelial cells are proved to produce BDNF [25]. In 
patients with angina pectoris, Jiang et  al. demonstrated 
that low plasma BDNF level was associated with a higher 
probability of major cardiovascular events than a middle 
level or a high level during the 4-year follow-up period 
[26]. Moreover, in a recently published population-based 
study, higher seBDNF was found to be associated with 
decreased risk of cardiovascular morbidity and mortality 
[6]. On the contrary, decreased serum BDNF was found 
to be associated with increased risk of incident stroke/
TIA [27]. In our study, the positive correlation with 
HDL and also with pulse pressure amplification, where 
higher values refer to better vascular conditions [28], 
also supports the plausible beneficial effect of BDNF in 
hypertension.
Some of the findings of our study were already 
described in the literature, such as the seBDNF correla-
tion with cholesterol and LDL [4], as well as with platelets 
[10]. As stored BDNF is released from platelets during 
clotting [10] and in essential hypertension, increased 
platelet activation is a trigger of hypercoagulable state 
[29], our finding that platelet count is positively corre-
lated with seBDNF may refer to a chief source of seBDNF 
in this pathological condition.
Another main finding of our study is that hyperthymic 
affective temperament is an independent determinant 
of seBDNF. This temperament is characterized by exu-
berant, upbeat, overenergetic, and overconfident life-
long traits [30]. We suppose that patients with higher 
hyperthymic temperament scores might have reduced 
inclination to cardiovascular complications, due to 
the beneficial effect of elevated seBDNF, a hypothesis 
that needs to be confirmed in follow-up studies. As the 
observed association between hyperthymic temperament 
score and seBDNF was only present in our hypertensive 
patients, we suppose an active role of affective tempera-
ments not only in psychiatric but also in cardiovascular 
pathophysiology.
Interestingly, in our study, no association of seBDNF 
with anxiety or depression was found. We suppose that 
this phenomenon can be explained by the mild anxiety 
and depression severity of HT patients.
Table 1 Demographic, laboratory, hemodynamic, and arte-
rial stiffness parameters; subjects’ questionnaire scores
CONT HT
N (male:female) 32 (12:20) 151 (58:93)
Age [year] 61.1 (55.9–70.5) 63.7 (57–71)
Duration of hypertension [year] – 11 (5–18)
Diabetes [n (%)] – 38 (25.2)
Cardiovascular disease [n (%)] – 21 (13.9)
Current smoker [n (%)] 3 (9.4) 22 (14.6)
Body height [cm] 168.8 ± 8.6 166.8 ± 8.6
Body weight [kg] 72.4 ± 12.1 79.7 ± 14*
BMI [kg/m2] 24.5 ± 5.4 28.6 ± 4.5*
Platelet count [G/l] 239.6 (215–277) 257 (209.7–303.2)
Glucose [mmol/l] 5.36 (4.88–5.81) 6.15 (5.11–6.7)*
GFR‑EPI [ml/min/1.73 m2] 79.7 (69.5–82.2) 77.9 (67–90)
Uric acid [µmol/l] 313.7 ± 11.6 318.4 ± 6.3
Cholesterol [mmol/l] 5.57 (4.97‑6.05) 5.18 (4.37- 5.98)*
LDL [mmol/l] 3.46 ± 0.91 3.07 ± 1.04
HDL [mmol/l] 1.68 (1.31–1.98) 1.40 (1.15–1.61)*
Triglyceride [mmol/l] 1.16 (0.75–1.43) 1.67 (1.08–2.06)*
Regular medication [n (%)]
 ACE inhibitors – 93 (61.5)
 ARBs – 34 (22.5)
 CCBs – 67 (44.4)
 Beta blockers – 87 (57.6)
 Diuretics – 68 (45)
 Antiplatelet drugs – 44 (29.1)
 Statins 5 (15.7) 54 (35.7)
 Alprazolam – 23 (15.2)
TEMPS‑A
 Depressive 5.9 (4–7) 7.1 (5–9)
 Cyclothymic 2.9 (0–4) 3.9 (1–6)
 Hyperthymic 11.2 ± 4 11 (4.2)
 Irritable 3.2 (2–4) 4.3 (2–6)
 Anxious 4.1 (1–6) 6.3 (2–9)
BDI 2.8 (1–4) 6.3 (3–9)*
HAM‑A 3.9 (1–6) 7.4 (2–10)*
Heart rate [1/min] 72.1 (66.6–78.2) 72.7 (64.1–77.2)
Brachial SBP [Hgmm] 125.5 ± 9.3 133.0 ± 12.3*
Brachial DBP [Hgmm] 72 ± 6.4 75 ± 9
Brachial PP [Hgmm] 51.5 (46.4–56.7) 56.7 (46.4–63)*
Central SBP [Hgmm] 117 (111.2–122.3) 124.1 (113.4–131.6)*
Central DBP [Hgmm] 67.1 ± 7 69.8 ± 8.2
Central PP [Hgmm] 49.9 (43.2–54.5) 54.3 (45.2–61)
PP amplification 1.08 (1.03–1.14) 1.07 (0.98–1.12)
PWV [m/sec] 8.6 (7.4–9.2) 9.3 (7.8–10)
Continuous data are presented as mean (SD) or mean (interquartile range)
Categorical parameters are presented as % (n)
BMI body mass index, ARBs angiotensin II receptor blockers, CCBs calcium 
channel blockers, SBP systolic blood pressure, DBP diastolic blood pressure, 
PP pulse pressure, PWV pulse wave velocity, AIx augmentation index, 
TEMPS-A Temperament Evaluation of Memphis, Pisa, Paris and San Diego 




AIx (%) 13.2 (5.75–23) 17.8 (8.5–25.1)
Serum BDNF (pg/ml) 21202.6 ± 6045.5 24880 ± 8279*
Table 1 countined
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In contrast to the literature, the presence of diabetes 
or the use of the benzodiazepine alprazolam was not sig-
nificantly correlated with seBDNF; however, the direc-
tion of correlations was as expected. We think that in 
both cases, the lack of significance was caused by the low 
proportion of diabetic or alprazolam user patients in our 
cohort.
The associations between seBDNF level and arterial 
stiffness parameters have never been evaluated in any 
patient population yet. Since BDNF has a relaxant effect 
on pulmonary arterial and aortic rings in different ani-
mal models [17, 18], we supposed a possible link between 
BDNF and arterial stiffness parameters. In contrast to 
this, in our study seBDNF showed an association only 
with pulse pressure amplification, but even this failed to 
be an independent predictor in regression analysis. We 
Table 2 The predictive values of hypertension and hyperthymic affective temperament score on serum BDNF level in dif-
ferent models evaluated with linear regression analysis in the whole study population (n = 183)
Hyp. temp. score hyperthymic affective temperament score, BDI Beck depression inventory, HAM-A Hamilton anxiety scale, Alp patients regularly using alprazolam, 
PPamp pulse pressure amplification
Models Beta Std. Error Std. Beta p R2
Model 1 0.036
 Hypertension 4149.6 1681.8 0.190 0.015
Model 2 0.050
 Hyp. temp. score 410.7 140 0.225 0.004
Model 3
 Hypertension + hyp. temp. score 0.089
 Hypertension 4310.3 1640.6 0.198 0.009
 Hyp. temp. score 422.2 137.6 0.231 0.003
Model 4: Model 3 + age + sex 0.107
 Hypertension 4365.1 1636.7 0.200 0.008
 Hyp. temp. score 449.8 138.1 0.246 >0.001
Model 5: Model 4 + diabetes 0.132
 Hypertension 5161.4 1661.2 0.237 0.002
 Hyp. temp. score 459.4 136.6 0.251 >0.001
Model 6: Model 5 + cholesterol + HDL 0.158
 Hypertension 5954.7 1685.5 0.273 >0.001
 Hyp. temp. score 430.6 136.8 0.235 0.002
Model 7: Model 6 + platelet number 0.176
 Hypertension 5540 1688.4 0.254 >0.001
 Hyp. temp. score 431.9 135.8 0.236 0.002
Model 8: Model 7 + BDI + HAM‑A + Alp. 0.191
 Hypertension 6167 1748.4 0.283 >0.001
 Hyp. temp. score 408 140.9 0.223 0.004
Model 9: Model 8 + PPamp. 0.202
 Hypertension 6121.2 1742.3 0.281 >0.001






















Hyperthymic affective temperament score (95% CI)
HT
CONT
Fig. 1 Association between serum BDNF level and hyperthymic 
affective temperament score in hypertensive patients (HT) and in 
controls (CONT). Continuous line with squares represents CONT, while 
broken line with rhombs represents HT
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suppose from these findings that seBDNF may exert its 
protective role rather on the level of the endothelium and 
perivascular nerves than on the level of large arteries.
The main limitation of our study comes from its cross-
sectional design which precludes causal inference. In 
addition, the number of the subjects involved into the 
study limited the number of potential confounding vari-
ables that were involved in the final regression model. 
Consequently, the presence of sleeping disorder, the 
amount of alcohol intake or the habit of regular exercise, 
variables with documented influence on BDNF level, were 
not involved into the final analysis (these were not signifi-
cantly correlated with seBDNF in univariate models, data 
are not shown). Moreover, other potential confounders, 
like childhood trauma, stress or sunlight exposition were 
not evaluated. In addition to these limitations, although 
we used standardized questionnaires and excluded 
patients with dementia, a complete exclusion of misinter-
pretations or mistakes by the patients is impossible.
Conclusions
In conclusions, our results suggest a complex psychoso-
matic involvement of BDNF in the pathophysiology of 
hypertension, where hyperthymic affective temperament 
may have a protective role. The impact of this phenom-
enon for cardiovascular outcome has to be clarified in 
prospective studies, but its mechanism is probably not 
mediated by large arteries.
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